Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mersana Therapeutics Inc.

0.3603
+0.01664.83%
Volume:1.11M
Turnover:395.95K
Market Cap:44.90M
PE:-0.60
High:0.3655
Open:0.3435
Low:0.3435
Close:0.3437
Loading ...

Mersana Therapeutics Inc - FDA Grants Two Fast Track Designations to Emi-Le

THOMSON REUTERS
·
2 hours ago

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 Asco Annual Meeting

THOMSON REUTERS
·
2 hours ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
20 May

Mersana Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
15 May

Mersana Therapeutics Reports Increased Net Loss of $24.1 Million and EPS of $0.19 for Q1 2025

Reuters
·
15 May

Mersana Therapeutics Q1 EPS $(0.19), Inline, Sales $2.75M Miss $5.84M Estimate

Benzinga
·
15 May

BRIEF-Mersana Therapeutics Q1 EPS USD -0.19

Reuters
·
15 May

Mersana Therapeutics Q1 EPS USD -0.19

THOMSON REUTERS
·
15 May

Mersana Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
13 May

Wedbush Cuts Price Target on Mersana Therapeutics to $3 From $4, Maintains Outperform Rating

MT Newswires Live
·
06 May

BUZZ-U.S. STOCKS ON THE MOVE-Datadog, Marriott, IQVIA

Reuters
·
06 May

BUZZ-Mersana Therapeutics announces restructuring plans; shares fall

Reuters
·
06 May

Mersana Therapeutics Inc: Will Also Reduce Its Research Activities and Eliminate Its Internal Pipeline Development Efforts

THOMSON REUTERS
·
06 May

Mersana Therapeutics Inc: Strategic Restructuring and Reprioritization Plan Will Reduce Company's Workforce by Approximately 55% Across Functions

THOMSON REUTERS
·
06 May

Mersana Therapeutics Inc: Workforce Reduction Is Expected to Be Substantially Complete by End of Q3 of 2025

THOMSON REUTERS
·
06 May

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

THOMSON REUTERS
·
06 May

Mersana Therapeutics : Cost-Saving Initiatives Expected to Extend Company's Cash Runway and Support Current Operating Plan Commitments Into Mid-2026

THOMSON REUTERS
·
06 May

Mersana Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

Reuters
·
05 May

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at Asco 2025 Annual Meeting

THOMSON REUTERS
·
23 Apr

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

GlobeNewswire
·
23 Apr